clinical trial

FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.

Moderna stock rises after positive Phase 1 hantavirus vaccine data, with analysts raising price targets amid signs of mRNA platform diversification beyond COVID.

Glucotrack submits IDE application for FDA clinical trial of implantable continuous glucose monitoring technology, marking major regulatory milestone for diabetes care innovation.

Arcutis reports Q1 2026 ZORYVE revenue of $105.4 million, up 65% year-over-year, with expanded pediatric development and reaffirmed full-year guidance of $480-495 million.

$ANNX set to showcase ARCHER II Phase 3 results targeting $1B+ geographic atrophy market at BofA Securities conference May 2026.

BioCryst posts 11% ORLADEYO revenue growth to $148.3M in Q1 2026, inks $70M European licensing deal for navenibart with up to $275M in milestones.

Kymera Therapeutics showcases KT-579 preclinical data matching approved IBD therapies ahead of Phase 1 trials in late 2026.

Eli Lilly reports durable four-year efficacy data for Omvoh in IBD, with 63.5% ulcerative colitis remission and 92.4% Crohn's response rates, bolstering pipeline confidence.

Portnoy Law Firm launches class action lawsuit against $SLNO alleging concealment of safety issues in lead drug DCCR, following 27% stock plunge.

Nektar Therapeutics faces securities class action lawsuit alleging REZOLVE-AA trial enrolled four ineligible patients, masking disappointing efficacy results.

Class action lawsuit filed against $NKTR for allegedly concealing REZOLVE-AA trial protocol violations and ineligible patient enrollment. Stock fell 7.77% on trial failure announcement.

AstraZeneca's prostate drug Truqap wins FDA panel backing (7-1 vote) for PTEN-deficient tumors, but breast cancer candidate camizestrant rejected despite superior efficacy data.

Rein Therapeutics prices $50M stock offering at $1.00 per share to fund LTI-03 Phase 2 trial for idiopathic pulmonary fibrosis, with cash runway extended through 2028.

Class action lawsuit filed against $SLNO alleging failure to disclose fluid retention safety concerns in DCCR drug trials, harming investors who bought shares March-November 2025.

Mesoblast reports Q3 FY2026 Ryoncil revenues of $30.3M, approaching $100M cumulative sales, while reducing operating cash spend and strengthening balance sheet.

Telix's next-gen prostate cancer therapy shows reduced organ toxicity in Phase 2 trial, expanding into earlier-stage disease applications with expanded clinical potential.

Tempest Therapeutics will present updated TPST-2003 CAR-T trial data at ISCT 2026, building on earlier 100% complete response rates in multiple myeloma patients.

Investors in $SLNO have until May 5, 2026 to join securities lawsuit alleging undisclosed safety issues with DCCR drug candidate.

Anteris Technologies secures CMS reimbursement eligibility for its PARADIGM Trial evaluating DurAVR transcatheter heart valve in 1,000 patients, accelerating U.S. site activation.

Telix Pharmaceuticals hosts webinar April 30 discussing next-gen PSMA cancer therapy pipeline, featuring OPTIMAL-PSMA2 trial data on TLX597-Tx candidate.